HTLV-2 infection in injection drug users in King County, Washington
- PMID: 16857611
- PMCID: PMC2683846
- DOI: 10.1080/00365540600617009
HTLV-2 infection in injection drug users in King County, Washington
Abstract
Human T-cell lymphotropic virus type 2 (HTLV-2) is endemic in injection drug users (IDU), and native American populations in the Americas. Transmission is associated with high-risk injection and sexual practices. A cohort of 2561 IDU in King County, Washington completed 2 study visits over 1 y. HTLV-2 infection was detected in 190 (7.4%) of 2561 IDU, and 13 (7.8 cases per 1000 person-y) incident infections occurred during the study. Prevalent infection was associated with female gender, non-white race, longer duration as IDU, having a tattoo, combined injection of heroin and cocaine, and with serologic evidence of hepatitis B and C infection. Seroconversion was more common in women, and was associated with African American race, heterosexual identity and longer duration as IDU. In conclusion, increased risk of HTLV-2 infection was associated with non-white race, and injection drug of choice, suggesting injection networks may play an important role in transmission of HTLV-2. The high correlation of HTLV-2 infection with HCV infection suggests the major route of transmission in IDU is via injection practices. Additional studies are needed to examine the clinical manifestations of HTLV-2 infection, as well as the clinical and virological manifestations of HTLV-2/HCV coinfection.
Similar articles
-
Molecular epidemiology of HTLV-II among United States blood donors and intravenous drug users: an age-cohort effect for HTLV-II RFLP type aO.Virology. 1998 Mar 15;242(2):425-34. doi: 10.1006/viro.1997.9009. Virology. 1998. PMID: 9514966
-
HTLV infection among young injection and non-injection heroin users in Spain: prevalence and correlates.J Clin Virol. 2006 Mar;35(3):244-9. doi: 10.1016/j.jcv.2005.06.006. Epub 2005 Sep 6. J Clin Virol. 2006. PMID: 16143565
-
Prevalence of HTLV types I and II among drug users in King County, Washington.West J Med. 1994 Jun;160(6):540-4. West J Med. 1994. PMID: 8053176 Free PMC article.
-
What is the situation of human T cell lymphotropic virus type II (HTLV-II) in Africa? Origin and dissemination of genomic subtypes.J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S228-35. doi: 10.1097/00042560-199600001-00034. J Acquir Immune Defic Syndr Hum Retrovirol. 1996. PMID: 8797728 Review.
-
The clinical epidemiology of human T-lymphotropic virus type II (HTLV-II).J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S215-9. doi: 10.1097/00042560-199600001-00032. J Acquir Immune Defic Syndr Hum Retrovirol. 1996. PMID: 8797726 Review.
Cited by
-
Human T-Lymphotropic Virus (HTLV): Epidemiology, Genetic, Pathogenesis, and Future Challenges.Viruses. 2025 May 1;17(5):664. doi: 10.3390/v17050664. Viruses. 2025. PMID: 40431676 Free PMC article. Review.
-
Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.Cochrane Database Syst Rev. 2017 Sep 18;9(9):CD012021. doi: 10.1002/14651858.CD012021.pub2. Cochrane Database Syst Rev. 2017. PMID: 28922449 Free PMC article.
-
Evaluation of the Inflammatory Cytokines and IL-10 Network in Individuals Co-infected With Human T-Cell Lymphotropic Virus and Hepatitis C Virus (HTLV/HCV).Front Microbiol. 2021 Feb 26;12:632695. doi: 10.3389/fmicb.2021.632695. eCollection 2021. Front Microbiol. 2021. PMID: 33717024 Free PMC article.
-
Human T-lymphotropic virus 2 (HTLV-2) prevalence of blood donors in the state of Pará, Brazil.Braz J Microbiol. 2023 Sep;54(3):1745-1750. doi: 10.1007/s42770-023-01067-2. Epub 2023 Jul 16. Braz J Microbiol. 2023. PMID: 37454039 Free PMC article.
-
Hepatitis C virus/human T lymphotropic virus 1/2 co-infection: Regional burden and virological outcomes in people who inject drugs.World J Virol. 2016 May 12;5(2):68-72. doi: 10.5501/wjv.v5.i2.68. World J Virol. 2016. PMID: 27175351 Free PMC article. Review.
References
-
- Feigal E, Murphy E, Vranizan K, Bacchetti P, Chaisson R, Drummond JE, et al. Human T-cell lymphotropic virus types I and II in intravenous drug users in San Francisco: risk factors associated with seropositivity. J Infect Dis. 1991;164:36–42. - PubMed
-
- Khabbaz RF, Onorato IM, Cannon RO, Hartley TM, Roberts B, Hosein B, et al. Seroprevalence of HTLV-1 and HTLV-2 among intravenous drug users and persons in clinics for sexually transmitted diseases. N Engl J Med. 1992;326:375–80. - PubMed
-
- Schwebke J, Calsyn D, Shriver K, Saxon A, Kleyn J, Oluoch-Mitchell E, et al. Prevalence and epidemiologic correlates of human T-cell lymphotropic virus infection among intravenous drug users. J Infect Dis. 1994;169:962–7. - PubMed
-
- Dourado I, Andrade T, Carpenter CL, Galvao-Castro B. Risk factors for human T-cell lymphotropic virus type I among injecting drug users in north-east Brazil: possibly greater efficiency of male to female transmission. Mem Inst Oswaldo Cruz. 1999;94:13–8. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources